Background -Obstruction of the superior vena cava (SVC) in malignant disease can cause considerable distress to patients. Symptomatic relief can be achieved by the percutaneous implantation of a selfexpanding stent (Wallstent) into the stenosis. Methods -Fourteen patients with obstruction ofthe SVC were treated with one to three Wallstent endoprostheses. They suffered from advanced bronchogenic carcinoma (n = 12), thyroid carcinoma (n = 1), and breast carcinoma (n = 1). The indication for stent placement was symptomatic obstruction of the SVC and incurable disease. Stenting was performed for symptom relief, and before, during, and after courses of radiotherapy or chemotherapy as needed. Results -Twelve patients experienced complete symptomatic relief within two days of stent placement. Two patients did not benefit. Three patients not given anticoagulation developed stent thrombosis between one week and eight months after initial placement, and within one day of endobronchial stent implantation with bronchial laser therapy or balloon dilatation in all three. Patency of the SVC was achieved again by a repeat procedure. Conclusions -Stent placement for obstruction of the SVC gives rapid symptomatic relief. Subsequent endobronchial stent implantation with bronchial laser therapy or balloon dilatation could be a risk for caval stent occlusion. Stent thrombosis remains a problem in patients who are not anticoagulated.
Stenosis and occlusion of the superior and inferior venae cavae and large veins can be a major problem in patients with malignant disease.' Obstruction is mostly due to compression or infiltration by tumour and may be complicated by secondary thrombosis. Bronchogenic carcinoma is the most common cause of an obstruction of the superior vena cava (SVC). Obstruction can also occur with postirradiation fibrosis or mediastinitis and in the venous outflow tract of arteriovenous dialysis shunts. In earlier reports a large percentage of cases of obstruction of the SVC were due to tuberculous mediastinitis and syphilitic aortic aneurysms. Obstruction of the SVC as a result of malignancy is conventionally treated by radiotherapy and/or chemotherapy.23 However, certain patients do not respond or there may be tumour recurrence. In some patients maximum chemotherapy or radiotherapy tolerance may already have been reached. Treatment of severe congestive symptoms with medication other than chemotherapy usually provides minimal relief. Venous stents seem to offer another alternative for the fast relief of symptoms. We placed intravenous stents in patients suffering from incurable malignant disease causing obstruction of the SVC. This approach has been reported using the Gianturco stent,4-13 the Wallstent,14-18 and the Palmaz stent.'9 We report on 14 patients treated with the self-expanding Wallstent.
Methods

PATIENTS
Fourteen patients (10 men) of age range 46-75 years (mean 62) were treated with 28 intravenous Wallstents (mean 2.0) (Schneider (Europe AG), Builach, Switzerland). Stent placement was performed for palliative treatment of incurable malignant compression of the SVC or innominate and subclavian veins (fig 1) with congestive symptoms in all patients. Twelve of the patients had carcinoma of the lung (four with small cell lung carcinoma), one patient had thyroid cancer, and one had breast cancer. The patient with thyroid cancer received an additional stent implantation in the internal jugular vein. The four patients with small cell lung carcinoma had chemotherapy before stenting, and also after venous stenting. Three patients with non-small cell lung carcinoma had had radiotherapy of the mediastinum before stenting and four further patients received radiotherapy after implantation of the venous stent. Two patients received endobronchial brachytherapy as additional radiotherapy. Informed consent was given by all 14 patients. STENT 
PROPERTIES
The Wallstent is non-ferromagnetic and MRI safe. It is constructed with filaments of medical grade stainless steel which are woven in a crisscross tubular pattern. The non-soldered crosspoints of the filaments give the stent flexibility and make it self-expanding. It is mounted on a catheter device which is introduced over a guidewire through an introducer. The stent is constrained by an outer membrane which can be retracted to release it. At full expansion the stent contracts by up to 70% of its constrained length, and this has to be considered when positioning it. A digital subtraction venogram of the stenosed veins was performed before stenting via a simultaneous injection, usually in a cubital vein, on both sides. After the initial venogram stent placement was planned according to the site and extent of the obstruction. Two patients had large areas of thrombus which was fragmented and lysed before the stenting. This was accomplished by pushing a guidewire through the thrombosis followed by a catheter with side holes which was introduced over it. Urokinase (up to 200 000 IU) was injected through the catheter into the thrombus. Fragmentation of the thrombus was achieved by moving the guidewire and catheter. In addition, a balloon catheter was inflated in the thrombus, compressing it against the vessel wall. A 0 035 inch diameter guidewire (Terumo Corporation, Tokyo, Japan) was then introduced via the antecubital cannula on one or both arms to traverse the stricture or occlusion and was advanced into a large pelvic vein. When this was not possible a right femoral vein approach was used. If the catheter coiled a stiffer guidewire was used. In one patient the right internal jugular vein was used. A sheath (7 or 9 French) was then introduced and the Wallstent endoprosthesis introduced over the guidewire (within the sheath) and positioned across the stricture. When released in a stenosis, the stent normally continues to expand its diameter for a few days. This can be accelerated by balloon dilatation within the stent and was done regularly in our patients. When there was a tight stenosis a balloon dilatation was performed before placement of the stent. The balloon catheter was introduced over the guidewire and placed at the site of stenosis. Dilatation was achieved by inflation of the balloon to a maximum diameter of 8-10 mm. Most procedures produced only slight dilatation. We selected a stent with a fully expanded diameter 1-2 mm larger than the estimated diameter of the vessel segment to be stented. In the SVC we used stents with an unconstrained diameter of 14 or 16 mm. When placed in a Y configuration in both innominate veins and in the SVC (fig 2) stents with an unconstrained diameter of 10 or 12 mm were used. When a stent placement into both the right and left innominate veins was necessary, this was performed sequentially from both cubital fossae. The caudal ends of the stents were placed one beside the other in the SVC, and the cranial ends in the right and left innominate veins. In other patients with long stenotic segments two or three overlapping stents were necessary and care was taken that the most caudal stent did not reach the right atrium. When the inflow of an internal jugular vein was to be bridged by a stent, the patency and normal lumen of the contralateral jugular vein was first verified. All the patients were given 5000 IU of heparin intravenously during the procedure. Lifelong anticoagulation therapy was maintained when thrombus was detected at the initial phlebography and in two of three patients after reintervention due to stent thrombosis. A third patient died several hours after reintervention. Anticoagulation varied in the other patients between none and lifelong. Blood pressure, pulse, electrocardiography, and arterial oxygen saturation were monitored in all patients during intervention and in the recovery area. 
